# A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

> **NCT07181837** · PHASE1,PHASE2 · RECRUITING · sponsor: **MavriX Bio, LLC** · enrollment: 12 (estimated)

## Conditions studied

- Angelman Syndrome

## Interventions

- **GENETIC:** MVX-220

## Key facts

- **NCT ID:** NCT07181837
- **Lead sponsor:** MavriX Bio, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-29
- **Primary completion:** 2028-03-31
- **Final completion:** 2031-05-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181837, "A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07181837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*